← Back to headlines
Grail slides as trial misses primary endpoint, fails to show significant stage III-IV cancer reduction
GRAIL has reiterated its guidance for 22%-32% Galleri sales growth by 2026 and plans to expand its sales force following the NHS-Galleri trial.
20 Feb, 09:41 — 20 Feb, 09:41
Sources
Showing 1 of 1 sources
Related Stories
Speedboat Collides with Sailboat in Eretria, Two Injured
1h ago
Penang CM: State remains under control after North Sumatra earthquake tremors
5h ago
Dolly Parton Misses Dollywood Event Due to Health Issues, Fans Concerned
6h ago
Supermarkets including Spar, Dirk and Plus warn of undercooked chicken thigh skewers
15h ago